Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21210136 | 1.00 | SIGMAR1 (0.41) | SIGMAR1TMEM97POLBHCRTR2LTA4H | |
| SCHEMBL13528036 | 1.00 | SIGMAR1 (0.41) | SIGMAR1TMEM97POLBHCRTR2LTA4H | |
| SCHEMBL21210139 | 1.00 | SIGMAR1 (0.41) | SIGMAR1TMEM97POLBHCRTR2LTA4H | |
| SCHEMBL13528035 | 1.00 | SIGMAR1 (0.41) | SIGMAR1TMEM97POLBHCRTR2LTA4H | |
| SCHEMBL13528037 | 1.00 | SIGMAR1 (0.41) | SIGMAR1TMEM97POLBHCRTR2LTA4H | |
| SCHEMBL16276085 | 0.84 | SIGMAR1 (0.44) | SIGMAR1TMEM97POLBLTA4H | |
| SCHEMBL6987664 | 0.82 | SIGMAR1 (0.39) | SIGMAR1TMEM97POLBHCRTR2HCRTR1 | |
| SCHEMBL20695777 | 0.80 | SIGMAR1 (0.50) | SIGMAR1POLB | |
| SCHEMBL9347312 | 0.79 | TMEM97 (0.41) | SIGMAR1TMEM97HCRTR2LTA4HHCRTR1 | |
| SCHEMBL646069 | 0.79 | TMEM97 (0.41) | SIGMAR1TMEM97HCRTR2LTA4HHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| CN-119325474-A | Spleen tyrosine kinase inhibitors | 尤尼奎斯特公司 | 2025-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | SIGMAR1 1904/4885TMEM97 2246/4885POLB 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.